Affording healthcare continues to be a hot topic – if not THE HOT TOPIC – in 2026. Patient Support Services play a crucial role in helping patients start and stay on therapy – and in today’s environment, getting the design right has never been more important. If you want to know more, there’s still time to register for our upcoming webinar, “𝗗𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗳𝗼𝗿 𝗜𝗺𝗽𝗮𝗰𝘁,” happening 𝗔𝗽𝗿𝗶𝗹 𝟭𝟲 at 𝟭𝟭𝗮𝗺 𝗘𝗧.
read full article ›Financial toxicity is front and center for patients, providers, and manufacturers alike. And yet, too many patient support programs (PSS) are still being built on assumptions rather than insights.
read full article ›As 35,000+ oncology professionals head to Chicago this week for hashtag#ASCO26, we'll hear remarkable science — new data, new approvals, new hope.
read full article ›Real Endpoints will be meeting at JP Morgan in January with a variety of folks on these and other issues – and would love to sit down with you as well. We can fill you in on what we see as the implications of policy and payer changes on coverage, reimbursement, and patient support; what we’re expecting for 2026; and discuss the specific topics you’re most concerned about.
read full article ›Real Endpoints board member Michael Sherman spells out the implications of recent Massachusetts-based GLP-1 coverage decisions for different healthcare stakeholders. Thing is these implications could also easily apply to any number of drugs in other competitive disease spaces, where there is high budget impact and more than a little uncertainty about clinical benefit.
read full article ›Sanofi’s $9B acquisition of Blueprint Medicines brings a welcome burst of heat to biotech’s long dealmaking winter. And it offers a few clear reminders about how access and reimbursement shape commercial value today.
read full article ›Thanks to the team at SwissHLG for inviting our CEO Jeff Berkowitz to discuss how early stage biotechs - and the investors who fund them - should invest in critical market access capabilities to drive commercial success.
read full article ›President Trump today signed an Executive order that, despite the pomp and circumstance, provided little to no detail on how it would be carried out. As expected, the order highlights Trump’s intent to use a “Most Favored Nation” strategy, in which U.S. prices will be tied to the lowest drug prices paid by developed countries.
read full article ›